Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

Investors may react cautiously to news that LUPIN's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.873000
forwardPE 23.174324
debtToEquity 31.513000
earningsGrowth 0.732000
revenueGrowth 0.242000
grossMargins 0.695230
operatingMargins 0.258370
trailingEps 94.350000
forwardEps 81.760000

LUPIN's current ratio of 1.873 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, LUPIN can comfortably cover its liabilities, reflecting a strong financial outlook.
Lupin Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
LUPIN's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
Positive gross and operating margins for LUPIN suggest that the company is operating profitably. These margins highlight LUPIN's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
Lupin Limited's forward EPS being lower than trailing EPS indicates reduced profitability in the upcoming year. This points to a potential decline in earnings, which could impact the company's financial strength.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

LUPIN's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect LUPIN to continue delivering solid performance in the future.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


Analysts' recent buy bias toward LUPIN suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see LUPIN as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.